全文获取类型
收费全文 | 1084816篇 |
免费 | 74358篇 |
国内免费 | 2379篇 |
专业分类
耳鼻咽喉 | 15126篇 |
儿科学 | 34734篇 |
妇产科学 | 28724篇 |
基础医学 | 154925篇 |
口腔科学 | 29818篇 |
临床医学 | 96529篇 |
内科学 | 205268篇 |
皮肤病学 | 24468篇 |
神经病学 | 82071篇 |
特种医学 | 43372篇 |
外国民族医学 | 211篇 |
外科学 | 164175篇 |
综合类 | 23934篇 |
现状与发展 | 3篇 |
一般理论 | 264篇 |
预防医学 | 75160篇 |
眼科学 | 24831篇 |
药学 | 87439篇 |
19篇 | |
中国医学 | 3496篇 |
肿瘤学 | 66986篇 |
出版年
2021年 | 8221篇 |
2019年 | 8196篇 |
2018年 | 11755篇 |
2017年 | 9340篇 |
2016年 | 10484篇 |
2015年 | 11836篇 |
2014年 | 15987篇 |
2013年 | 22835篇 |
2012年 | 31456篇 |
2011年 | 33397篇 |
2010年 | 19537篇 |
2009年 | 18314篇 |
2008年 | 30590篇 |
2007年 | 32674篇 |
2006年 | 33355篇 |
2005年 | 31702篇 |
2004年 | 30150篇 |
2003年 | 28911篇 |
2002年 | 27851篇 |
2001年 | 60251篇 |
2000年 | 61724篇 |
1999年 | 51251篇 |
1998年 | 12664篇 |
1997年 | 11213篇 |
1996年 | 11153篇 |
1995年 | 10464篇 |
1994年 | 9445篇 |
1993年 | 8934篇 |
1992年 | 37861篇 |
1991年 | 36347篇 |
1990年 | 35815篇 |
1989年 | 34334篇 |
1988年 | 30905篇 |
1987年 | 30006篇 |
1986年 | 28246篇 |
1985年 | 26482篇 |
1984年 | 19209篇 |
1983年 | 16122篇 |
1982年 | 8827篇 |
1979年 | 17035篇 |
1978年 | 11404篇 |
1977年 | 10229篇 |
1976年 | 8838篇 |
1975年 | 10068篇 |
1974年 | 11651篇 |
1973年 | 11273篇 |
1972年 | 10754篇 |
1971年 | 10092篇 |
1970年 | 9252篇 |
1969年 | 8938篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Hassen Lena M. Albarrak Rana A. Albahlal Reem A. Alsaqabi Dimah K. Hassen Ikhlass M. Daghestani Maha H. Alqurtas Eman M. Alkhalaf Abdulaziz T. Bedaiwi Mohammed K. Omair Mohammed A. Almaghlouth Ibrahim A. 《Quality of life research》2022,31(11):3229-3239
Quality of Life Research - The COVID-19 pandemic might add to the stressors experienced by people living with rheumatic diseases. This study aimed to examine rheumatic patients’ functional... 相似文献
3.
Molnár B. Aroca S. Dobos A. Orbán K. Szabó J. Windisch P. Stähli A. Sculean A. 《Clinical oral investigations》2022,26(12):7135-7142
Clinical Oral Investigations - To evaluate t he long-term outcomes following treatment of RT 1 multiple adjacent gingival recessions (MAGR) using the modified coronally advanced tunnel (MCAT) with... 相似文献
4.
Zeyu Li Erwei Hao Rui Cao Si Lin Linghui Zou Tianyan Huang Zhengcai Du Xiaotao Hou Jiagang Deng 《中草药(英文版)》2022,14(4):479-493
Zedoary tumeric (Curcumae Rhizoma, Ezhu in Chinese) has a long history of application and has great potential in the treatment of liver cancer. The anti liver cancer effect of zedoary tumeric depends on the combined action of multiple pharmacodynamic substances. In order to clarify the specific mechanism of zedoary tumeric against liver cancer, this paper first analyzes the mechanism of its single pharmacodynamic substance against liver cancer, and then verifies the joint anti liver cancer mechanism of its "pharmacodynamic group". By searching the research on the anti hepatoma effect of active components of zedoary tumeric in recent years, we found that pharmacodynamic substances, including curcumol, zedoarondiol, curcumenol, curzerenone, curdione, curcumin, germacrone, β-elemene, can act on multi-target and multi-channel to play an anti hepatoma role. For example, curcumin can regulate miR, GLO1, CD133, VEGF, YAP, LIN28B, GPR81, HCAR-1, P53 and PI3K/Akt/mTOR, HSP70/TLR4 and NF-κB. Wnt/TGF/EMT, Nrf2/Keap1, JAK/STAT and other pathways play an anti hepatoma role. Network pharmacological analysis showed that the core targets of the "pharmacodynamic group" for anti-life cancer are AKT1, EGFR, MAPK8, etc, and the core pathways are neuroactive live receiver interaction, nitrogen metabolism, HIF-1 signaling pathway, etc. At the same time, by comparing and analyzing the relationship between the specific mechanisms of pharmacodynamic substance and "pharmacodynamic group", it is found that they have great reference significance in target, pathway, biological function, determination of core pharmacodynamic components, formation of core target protein interaction, in-depth research of single pharmacodynamic substance, increasing curative effect and so on. By analyzing the internal mechanism of zedoary tumeric pharmacodynamic substance and "pharmacodynamic group" in the treatment of liver cancer, this paper intends to provide some ideas and references for the deeper pharmacological research of zedoary tumeric and the relationship between pharmacodynamic substance and "pharmacodynamic group". 相似文献
5.
瞬时受体电位亚家族V成员6 (Transient Receptor Potential Channel Subfamily V Member 6, TRPV6) 是一种钙离子高度选择性离子通道,在多种组织中均有表达,控制细胞顶端钙离子的进入,在维持钙稳态中发挥重要作用。TRPV6功能异常会影响体内钙稳态,进而引发新生儿骨骼发育异常、甲状旁腺功能亢进、骨与软骨代谢异常、肾结石和高尿钙症、 以及炎症性肠病和慢性胰腺炎等多种疾病。近年来研究也表明,TRPV6的上调与多种肿瘤的侵袭性增加有关,具有作为肿瘤检测的标志物以及治疗靶点的潜力。本综述将聚焦于TRPV6与其在相关疾病中发挥的作用,旨在为TRPV6作为药物靶点实现临床转化提供理论依据。 相似文献
6.
7.
8.
9.
10.
Jesus K Yamamoto-Furusho Norma N Parra-Holgu n 《World journal of gastroenterology : WJG》2021,27(48):8242-8261
Inflammatory bowel disease (IBD) is a chronic disease that requires chronic treatment throughout the evolution of the disease, with a complex physiopathology that entails great challenges for the development of new and specific treatments for ulcerative colitis and Crohn´s disease. The anti-tumor necrosis factor alpha therapy has impacted the clinical course of IBD in those patients who do not respond to conventional treatment, so there is a need to develop new therapies and markers of treatment response. Various pathways involved in the development of the disease are known and the new therapies have focused on blocking the inflammatory process at the gastrointestinal level by oral, intravenous, subcutaneous, and topical route. All these new therapies can lead to more personalized treatments with higher success rates and fewer relapses. These treatments have not only focused on clinical remission, but also on achieving macroscopic changes at the endoscopic level and microscopic changes by achieving mucosal healing. These treatments are mainly based on modifying signaling pathways, by blocking receptors or ligands, reducing cell migration and maintaining the integrity of the epithelial barrier. Therefore, this review presents the efficacy and safety of the new treatments that are currently under study and the advances that have been made in this area in recent years. 相似文献